flying bird

Tricks and Tips

Wednesday, 27 March 2019

CORPORATE NEWS By CapitalStars 27/Mar/2019


corporate news

Lupin gets USFDA approval for Tadalafil Tablets USP
Pharma major Lupin Limited (Lupin) announced that it has received approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.
Lupin Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, is the generic equivalent of Eli Lilly and Company Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. It is indicated for the treatment of:
Erectile dysfunction (ED)
The signs and symptoms of benign prostatic hyperplasia (BPH)
ED and the signs and symptoms of BPH (ED/BPH).

Strides Pharma gets USFDA approval for oral dosage facility in Singapore
Strides Pharma Science Limited (Strides) has received USFDA approval for its Greenfield oral dosage facility in Singapore. With the commercialization of its manufacturing facility in Singapore, Strides will join the league of global pharmaceutical companies having a Manufacturing and Research and Development footprint in Singapore, the company said in the filing.
The facility will complement Strides existing manufacturing base and will help meet increased demand from its fast rowing regulated markets business across the US, Australia, UK and Europe.

Cadila arm receives 1 observation from USFDA for Ahmedabad plant
Cadila in its filing to the exchanges on Wednesday informed that the companys Alidac Pharmaceuticals received one observation from the USFDA for its injectable onco manufacturing facility, located at Pharmez, Ahmedabad.
The USFDA had conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals Ltd, the injectable onco manufacturing facility from March 18 to 26, 2019, the company said in a press note.

Tata Power stock rises 2% after MERC approves 700 MW PPA
Shares of Tata Power rose 2% on the BSE in the afternoon session after the company has received approval from Maharashtra Electricity Regulatory Commission (MERC) approval to supply the power from its Trombay Thermal and Hydro plants.
Maharashtra Electricity Regulatory Commission (MERC) has allowed the Distribution Business of Tata Power, India largest integrated power utility to have a Power Purchase Arrangement (PPA) with its generation arm for 700 MW to be supplied from its Trombay Thermal and Hydro plants for a period of five years from April 1, 2019 to March 31, 2024, the company said in the BSE filing.

ICICI Prudential Life gains 9% after OFS subscribes 3.9 times
Shares of ICICI Prudential Life Insurance gains 9% on Wednesday after the offer for sale (OFS) of the company witnessed subscription of 3.9 times.
Accordingly, investors bid for 210mn shares against 53.26mn on shares on offer. The 53.2 mn share sale will fetch Prudential ~Rs1,598cr. The floor price for the sale has been fixed at Rs300, a discount of 7% to Monday closing price of Rs322.35.




Investment  trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
 
For more details call on 9977499927 or visit our website www.capitalstars.com

0 comments:

Post a Comment